Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

The m5C-binding protein YB-1 modulates proteasome inhibitors resistance in multiple myeloma via epigenetic modification

Qiqi Shen, Xi Huang, Shunnan Yao, Enfan Zhang, Zhen Cai

Blood (2025) 146 (Supplement 1): 5700.

https://doi.org/10.1182/blood-2025-5700

Published: 2025

Journal Articles

Targeting CCR7 ubiquitination to disrupt protumoral macrophages: A NEDD4-1-dependent strategy to reverse bortezomib resistance in myeloma

Xi Huang, Shunnan Yao, Enfan Zhang, Zhen Cai

Blood (2025) 146 (Supplement 1): 5719.

https://doi.org/10.1182/blood-2025-5719

Published: 2025

Journal Articles

NAMPT in macrophages promotes multiple myeloma drug resistance through mitochondrial metabolic reprogramming and modulates immunosuppression via the SIRT1/STAT3/SPP1 axis.

Shunnan Yao, Gang Xiao, Xi Huang, Qiqi Shen, Haoguang Chen, Chunting Zhu, Shengchun Jin, Enfan Zhang, Zhen Cai

Blood (2025) 146 (Supplement 1): 5707.

https://doi.org/10.1182/blood-2025-5707

Published: 2025

Journal Articles

Super-enhancer-mediated regulation of CD38 inducibility in multiple myeloma via the MAF/TRIM47/RARα axis

Zhenfeng Dai, Yunlu Jia, Qiqi Shen, Haoguang Chen, Xinyuan Dai, Shengchun Jin, Enfan Zhang, Jianbiao Zhou, Gang Xiao, Wee-joo Chng, Zhen Cai

Blood (2025) 146 (Supplement 1): 2156.

https://doi.org/10.1182/blood-2025-2156

Published: 2025

Journal Articles

Characteristics of immune genes rearrangements in Chinese multiple myeloma patients

Donghua He, Yang Yang, Yiwei Zhou, Enfan Zhang, Li Yang, Xiaoyan Han, Jingsong He, Zhen Cai

Blood (2025) 146 (Supplement 1): 5759.

https://doi.org/10.1182/blood-2025-5759

Published: 2025

Journal Articles

Deciphering the cellular hierarchy of multiple myeloma uncovers a therapeutically exploitable EP300/TBX2 axis in LILRB4+ myeloma-initiating cells

Haoguang Chen, Shanshan Pei, Qiqi Shen, Zhenfeng Dai, Shunnan Yao, Enfan Zhang, Zhen Cai

Blood (2025) 146 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2025-2170

Published: 2025

Journal Articles

Myeloma-Associated Macrophages Protect Tumor Cells By Reprogramming of Lipid Metabolism through SREBP1

Xing Guo, Zhenfeng Dai, Enfan Zhang, Zhen Cai

Blood (2024) 144 (Supplement 1): 6858.

https://doi.org/10.1182/blood-2024-210568

Published: 2024

Journal Articles

E3 Ubiquitin Ligase TRIM21 Enhances Macrophage-Mediated Bortezomib Resistance By Inducing M2 Polarization in Multiple Myeloma

Wen Cao, Jing Chen, Enfan Zhang, Zhen Cai

Blood (2024) 144 (Supplement 1): 6829.

https://doi.org/10.1182/blood-2024-209627

Published: 2024

Journal Articles

A Positive Feedback Loop between YTHDC1 and EP300 Drives Tumorigenesis in Multiple Myeloma

Yifan Hou, Jianwei Qu, Enfan Zhang, Zhen Cai

Blood (2024) 144 (Supplement 1): 4647.

https://doi.org/10.1182/blood-2024-207016

Published: 2024

Journal Articles

The Ratio of Urea Nitrogen to Albumin Is a Better Predictor of OS in MM Patients Than That of Urea Nitrogen Alone

Mengmeng Dong, Jiaqi Shao, Enfan Zhang, Haoguang Chen, Zhen Cai, Tao Cheng

Blood (2023) 142 (Supplement 1): 6688.

https://doi.org/10.1182/blood-2023-184847

Published: 2023

Journal Articles

E3 Ubiquitin Ligase TRIM21 Enhances Macrophage-Mediated Bortezomib Resistance By Inducing M2 Polarization in Multiple Myeloma

Wen Cao, Jing Chen, Enfan Zhang, Zhen Cai

Blood (2023) 142 (Supplement 1): 5730.

https://doi.org/10.1182/blood-2023-174448

Published: 2023

Journal Articles

Gain or Amplification of Chromosome 1q Mediate Multiple Myeloma Resistant to Xpo-1 Inhibitor Selinexor Via Transcription Factor ETV3

Huiyao Gu, Yi Zhong, Enfan Zhang, Liqin Cao, Zhen Cai, Jingsong He

Blood (2023) 142 (Supplement 1): 6579.

https://doi.org/10.1182/blood-2023-184720

Published: 2023

Journal Articles

Increase of Dnts Correlated with Clinic Outcome after Allogeneic DNT Cells Infusion in r/r AML Patients

Huiyao Gu, Donghua He, Xiaofeng Han, Yi Li, Li Yang, Enfan Zhang, Haicun Xie, Yu Cheng, Fuqiang Wu, Guangrong Song, Daqing Liu, Liming Yang, Jingsong He, Zhen Cai

Blood (2023) 142 (Supplement 1): 6867.

https://doi.org/10.1182/blood-2023-186221

Published: 2023

Journal Articles

Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma:Pathological Phenotype and Genetic Mutation Analysis of 12 Patients

Linlin Huang, Hanjin Yang, Yang Yang, Fang Yu, Yi Zhao, Xiujin Ye, Weiyan Zheng, Jie Sun, Enfan Zhang, Zhen Cai, Jingsong He

Blood (2023) 142 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2023-186056

Published: 2023

Journal Articles

EGFR and HDAC Dual-Target Inhibitor CUDC-101 Enhances the Anti-Myeloma Effects of Bortezomib By Regulating the G2/M Cell Cycle Arrest

Wen Cao, Enfan Zhang, He Huang, Jing Chen, Yang Liu, Zhen Cai

Blood (2022) 140 (Supplement 1): 12438.

https://doi.org/10.1182/blood-2022-157171

Published: 2022

Journal Articles

FGFR1OP2 Promotes Proliferation and Survival of Myeloma Cells and Is a Potential Therapeutic Target

Yang Yang, Enfan Zhang, He Huang, Zhen Cai

Blood (2022) 140 (Supplement 1): 12464–12465.

https://doi.org/10.1182/blood-2022-169373

Published: 2022

Journal Articles

Cytomegalovirus and Epstein-Barr Virus Infection during Daratumumab Treatment in Patients with Multiple Myeloma

Shuchan Li, Xiaoyan Han, Enfan Zhang, He Huang, Zhen Cai

Blood (2022) 140 (Supplement 1): 12490–12491.

https://doi.org/10.1182/blood-2022-164522

Published: 2022

Journal Articles

The Efficacy of Residual Plerixafor of Second-Day Stem Cell Mobilization in Multiple Myeloma Patients

Donghua He, Chunting Zhu, Xing Guo, Xin Huang, Xiaoyan Han, GaoFeng Zheng, Yi Zhao, Yang Yang, Wenjun Wu, Jimei Ge, Enfan Zhang, He Huang, Jingsong He, Zhen Cai

Blood (2022) 140 (Supplement 1): 12813–12814.

https://doi.org/10.1182/blood-2022-166394

Published: 2022

Journal Articles

ALKBH5 Functions As an Oncogene in Multiple Myeloma

Jianwei Qu, Yifan Hou, Qingxiao Chen, Jing Chen, YI LI, Enfan Zhang, Huiyao Gu, Ruyi Xu, Yang Liu, Jingsong He, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2021-149622

Published: 2021

Journal Articles

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Yi Li, Jingsong He, Xiaoyan Han, Gaofeng Zheng, Enfan Zhang, Qingxiao Chen, Donghua He, Yi Zhao, Jiaping Fu, Lihong Shou, Wenhua Jiang, Wei Jiang, Shenxian Qian, Huixian Hu, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2021-149188

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The m5C-binding protein YB-1 modulates proteasome inhibitors resistance in multiple myeloma via epigenetic modification

Targeting CCR7 ubiquitination to disrupt protumoral macrophages: A NEDD4-1-dependent strategy to reverse bortezomib resistance in myeloma

NAMPT in macrophages promotes multiple myeloma drug resistance through mitochondrial metabolic reprogramming and modulates immunosuppression via the SIRT1/STAT3/SPP1 axis.

Super-enhancer-mediated regulation of CD38 inducibility in multiple myeloma via the MAF/TRIM47/RARα axis

Characteristics of immune genes rearrangements in Chinese multiple myeloma patients

Deciphering the cellular hierarchy of multiple myeloma uncovers a therapeutically exploitable EP300/TBX2 axis in LILRB4+ myeloma-initiating cells

Myeloma-Associated Macrophages Protect Tumor Cells By Reprogramming of Lipid Metabolism through SREBP1

E3 Ubiquitin Ligase TRIM21 Enhances Macrophage-Mediated Bortezomib Resistance By Inducing M2 Polarization in Multiple Myeloma

A Positive Feedback Loop between YTHDC1 and EP300 Drives Tumorigenesis in Multiple Myeloma

The Ratio of Urea Nitrogen to Albumin Is a Better Predictor of OS in MM Patients Than That of Urea Nitrogen Alone

E3 Ubiquitin Ligase TRIM21 Enhances Macrophage-Mediated Bortezomib Resistance By Inducing M2 Polarization in Multiple Myeloma

Gain or Amplification of Chromosome 1q Mediate Multiple Myeloma Resistant to Xpo-1 Inhibitor Selinexor Via Transcription Factor ETV3

Increase of Dnts Correlated with Clinic Outcome after Allogeneic DNT Cells Infusion in r/r AML Patients

Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma:Pathological Phenotype and Genetic Mutation Analysis of 12 Patients

EGFR and HDAC Dual-Target Inhibitor CUDC-101 Enhances the Anti-Myeloma Effects of Bortezomib By Regulating the G2/M Cell Cycle Arrest

FGFR1OP2 Promotes Proliferation and Survival of Myeloma Cells and Is a Potential Therapeutic Target

Cytomegalovirus and Epstein-Barr Virus Infection during Daratumumab Treatment in Patients with Multiple Myeloma

The Efficacy of Residual Plerixafor of Second-Day Stem Cell Mobilization in Multiple Myeloma Patients

ALKBH5 Functions As an Oncogene in Multiple Myeloma

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only